Genentech, a member of the Roche Group RHHBY,
today announced final results from the Phase III AVAglio study in people
with newly diagnosed glioblastoma, the most common and aggressive form
of primary brain cancer. Final results confirmed people who received
Avastin® (bevacizumab) plus radiotherapy and temozolomide
chemotherapy benefited from a significant improvement in
progression-free survival (PFS) compared to those who received placebo
plus radiotherapy and temozolomide chemotherapy. Overall survival (OS)
was not significantly improved in the study.
As previously announced, Avastin plus radiotherapy and temozolomide
chemotherapy significantly reduced the risk of the glioblastoma
worsening or death by 36 percent compared to radiotherapy and
temozolomide chemotherapy plus
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in